H.C. Wainwright initiated coverage of FibroGen (FGEN) with a Buy rating and $10 price target The company’s lead asset, FG-3246, is a novel antibody drug conjugate targeting CD46 expressing tumors, the analyst tells investors in a research note. The firm says FibroGen’s pipeline “could be a whole new ball game” in metastatic castration-resistant prostate cancer and beyond.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
Questions or Comments about the article? Write to editor@tipranks.com